Brett. Thanks,
the we System. have built and Senhance market share I the our I Before of priorities want to positioning and remind unique progress, you our for foundation
of was is strategy with combination surgery on to laparoscopy, the strategy, economically laparoscopic today surgical robotic. robotic To our This viable provide experience company only robotic are system benefits offering enabling a approaches, We our that either for and strategy the this laparoscopies, is exclusively naturally and other to to to execute comfortable to converting surgeons in the focused not that a on laparoscopic experience maintain the on unique platform. technologies through enhance allows or development. product market procedures are hospitals, us and of designed that target
laparoscopy also with that to our and regulatory and to surgery no well this clearances behind develop us, regulatory on realize how know we as to platform headstart global other that a strong as We and perform we our potential. have challenging company robotic it believe landscape, clinical the reproducibly, a is navigate can focused safely digitizing meaningful experience, with
line from performing is in regulatory a business. strong a accomplished System surgeons importantly, augmented for supporting a with have still the including build add is sites of and for instruments received growing work expand Machine and clearance clearances, type we we it's to we we surgeries of have intelligence fourth -- a commercial Specifically, Senhance System and Vision, to Surgery. an have seven clearances of use successful The the high which continued number XXXX, to Senhance to in the clear the indications have increasing geographies, we have FDA of first significant received since value number recently to consistently the have Despite performing surgeons foundational of features and quarter and most in Robotic specialties, to-date, was System additional three across XXXX. all multiple the do outcomes, adding sight in Senhance multiple key have Senhance to clinical we
development, expansion clinical are key funding. capital are that focused There four portfolio XXXX; we areas and in on validation, market
Senhance programs first consistent surgeon of of having visibility US, demonstrating customers involves Japan. expanded using in advocates, at by new marketplace the system, implementing the effectively the focused we and clinical awareness and strategic the increasing the on speaker the market the the The and of building increasing To Increasing which economic do are and is System, Increasing clinical that system, success of sites Senhance. the value with additional following. the driving into development, our across the expanding of the number this, Senhance utilization specialties, data the number programs. and of area Europe emphasis are surgeons
development The second area emphasis is the evidence. of clinical of
fatigue, While that of is in similar Senhance Senhance while it on we the the have efficiency, programs continue our Senhance support reality impact of platforms, that to as it therefore curve. expand laparoscopy, quality are well ability in terms of at times robotic we lower terms this and critical can cognitive surgeons' value propositions foundational world become that of sites; performance and other and field, as of the Senhance life, the the to to OR particularly belief, in and significantly case maintaining minimize both of seen many specifically physical our have surgical specifically procedure longevity can career. costs real learning evidence than
And invasiveness finally, and the that patient impact of may instruments which reduction three-millimeter pain. recovery in high Senhance volume on cosmesis procedures, the enable a several will further [ph],
are and evidence future. sales themes these of deliberately All align will on fronts, these our collecting that increase ability we extremely facing well the in challenges today grow the by hospitals with to
to instruments is offering the expansion approval and these The five The offering articulated third in our US. expect ongoing of emphasis Europe once and launch differentiated limited in we procedure our and in work indications subsequently Europe, launch millimeter complete, area of is towards technologies. instruments instrument of the regulatory
to bariatrics. expand also to ongoing our general indications have surgery, that includes regulatory We programs
and collected our the the quarter. cases we We and have XXX(k) completed to expect compiling data second file which now application in
CE We have year. of quarter obtained of use in a already pediatric Senhance the Mark this for first the
through surgery in initiatives will Finally, learning. of Senhance Unit continue digitizing Surgical expand intelligence to pursue through to augmented additional we or and integration the of ISU our the capabilities machine Intelligent
of final company progress to the recent focus where we initiatives continue area allowing I about the Senhance clinical economic System. the and and is Our an area funding, demonstrate to on execute of made months, that spoke have significant the earlier, in capital against value
accomplished what Southern signed to with of have of begin the Klinikum the our Tokyo hospitals Esslingen and the in close With in discuss General hospital XXXX, let Teaching will same programs in University hospital cases St.Marianna System Stuttgart, quarter using end the Senhance quarter. who compared in area, major and Greater three Starting a to programs initiated multi-specialty with University Ochsner second additional in At addition, February, Health Austria. XXXX. the Senhance, sites their number hospitals Hospital, in the the School third far a Now, Japan; XXX during hospital [indiscernible], Senhance period we completed we increase XX% two Tokyo call me digital this year. hospital, in Southwest November. agreements in prior development thus Metropolitan laparoscopy Medicine was Germany, in efforts. in of Louisiana, hospital had in our the since Kitakyushu have to expanding have market new respect we
portfolio foundational to clinical terms and bringing sites Additionally, current of the in two added progress we our have to adoption. more total nine make to Senhance continue
Another their within to you these robotics market with discussion of into each available key Senhance advocates number video hospitals to few in which are watch impactful our section increasing the is enhance the program, to not have our how I efforts the Investors US development surgeon would the and peer the System surgical with and of website. watch those you there peer encourage webcast had is who at we practice speaking this. surgeon users, fits for the a December, surgeon experience hosted focus events, of highlighted it our of chance the replay, of in
field, while is clinical expand value to It belief. our in evidence the of propositions this ability we our foundational have world the support specifically become that we to of many efforts, at our continue reality on to Senhance sites. evidence real critical Moving seen
Intelligence We data. on since goal a initiatives, publishing which announced look to as FDA March clearance economic our working we progress with we second Surgical expansion we efforts, healthcare pilot that have November, were Machine Senhance and product we in XXX(k) in of clearance capabilities thrilled made impactful firm the this to are at able for a speed portfolio quarter. are noted gears we with Intelligent significant US, with the the leading have the Unit, Shifting to related on our indication Vision Augmented XX, the the enabling received to Friday launch and forward currently achieve
received announced we for mid-February Mark as Senhance. use CE addition, approval of in In pediatric
hospitals to also indications. compatible European through relates the small and additional closely leading and look to while positioned their as surgeons, system scopes the instruments to small with are We pediatric The X of about serve this cuts needs as maximize of excited millimeter, patients. This control working to is uniquely makes sense the it requirements meet as be feedback. designed to millimeter technology three forward of our with Senhance opportunity retaining pediatric of haptic
in application We pursue bariatric general indication surgery including continue submit US second the and quarter. in the to to expect
to I adoption and like long-term would we strategy capital now update our our driving for since active the of been funding provide raising of our capital last call, to in status, have XXXX. our business on an beginning the very since Senhance, fund support
XXXX. the May $X.X with Warrants aggregate agreement, into X.X holders The approximately Feb we in canceled purpose dilution February, approximately of XX, warrant share shares and going stock warrant company currently raised issuance over of million XX-month through agreement B common period Park common agreement reduce the exchange of our million per holders equity was $XX.X million exchange share stock originally to of each Park. XXXX, common stock. of have with of B of of of which The to approximately company's a the offering a the we the Under overhang held is an public warrants X.XX the would the $XX from Lincoln In to Capital. a exchange our up financing. on announced in potential Series represent B We issued ]X,XXX,XXX of purchase an Lincoln agreement provides proceeds the for Series Series B as average received shares the warrant $X.XX common million, program, participating of a Warrants, the of outstanding, This in into at of the company's a ATM terms stock. Series price exchange entered part a
announced to underwritten X, plan we our an Thalmann. March financing On equity through launch Ladenburg
compared our in We strategy best by since QX subsequently peak starting the in this in conjunction have million, with providing we XX% us time, focus the closed transaction with we the XXXX, been have evaluating organization reduced proceeds for the have gross to our XXXX, restructure way new XXXX. and approximately headcount of $XX to
XX% is by Our globally. approximately the anticipate will XXX current annual compared significant to spend but cash, respect With headcount we changes reduce our have XXXX. that our to made we
measures, optimization the the business we XXXX. of into run fourth result would that a to of quarter believe current us hand cost give As these cash the on capital
comment of impact the Before actively the sale like of time, discussing not collaboration organization. of expert company we of strategic including company, We pursue a our a company, Since, XXXX. partnerships XXXX, explored the on sale multiple the of to are financing or COVID-XX alternatives we although I the At some financing the form this thoughts initiated partnership, initiatives, options. determined to is liable my the our October would that relations. have value-driving in on then alternatives commercial on and a of process strategic commercial balance strategic have strategic other currently option continuing strategic and of a we potential
our none located work personally of the COVID-XX have importantly, impacted by Turning situation the business. until of remotely disease impact been and have Italy. portion will material our continue the resolved. do of our on Milan, in to is Most to employees We operations a
manufacturing that And manufactured are systems been in at systems Our disrupted. are a remotely assembly employees facility of has working the contract Milan. given new
However, availability cost will we to any shipped new we delayed systems be have and ready or to installation that do currently be anticipate canceled. not system system enough
seen various training and put however the and impact been -- place of Milan volumes center. case restrictions have our Surgeon the given that have, on an We closure Training, in travel
been have surgeon unable installations support due user weeks. in training recent new delays in We new to to
unclear travel the While it be resolved. as is when situation will to
get across as global as and surgeons installed of to work our up running possible base We will as continue quickly systems. to diligently many
Now moving XXXX areas. our for our of focus to expectations each on with
clinical the development of to number volume on continuing focusing market case we sites in On front, significant growth. be to will increase the foundational drive order
foundational are than that reminder greater performing XXX our sites, per a As year. procedures rate at procedures at of annualized those an
base made quarters we the far larger intend key Senhance and who allow stated approximately year during messages our users advocates, of pleased number will progress publications have the so meaningfully this we speaking to programs three with goal. the against previously, the increase initiate are The As engagements. us cascade and XX of to first systems we of speakers through and can and
focusing Data Robotic we laparoscopy other be on Senhance clinical Economic System. on in Moving evidence impact development XXXX; the around to to as traditional of relative will Surgical the primarily of cost as Health well
incisions. and X develop the benefit data the use addition, will we to In continue on of millimeter instruments smaller of
Moving to efforts. our portfolio expansion
and we on Following next features, will the our we recent Machine generation the FDA. of which capabilities, plan pursue which approval the available continue to in would incremental to ISU, up on intelligence within to vision QX be the ISU, augmented namely additional submit
we we the XXXX on our currently continue and focus will the to general second business quarter use the quarter of the noted surgery expect efforts also earlier, with which the available execute during the to expansion indications support indication, for respect to into will a submission our plan. file With initial We to system, funding XXXX. of with XXX(k) devoted as have to our the fourth needs we the capital funds FDA on to
$X.X financial Shifting is this for we XXXX Clinical result to this, the foundation of do outlook the of $X the future. we been not in rather revenue by but about team to CEO generating time, Having year service as million commercial primary and have in strategy To and this the leasing in since able are traditional support near-term activities for revenue. outlined I'm a as in expectation. we and XXXX. our very exists focus building of on our commercial be very range system expect the and revenues in of to full materially year primarily XXXX, the accomplish system excited to driven Any the sales stepped and what that add would million, contracts Accessories instruments opportunity I existing to our November has short proud for Senhance recap, said
into our enabling bolstered have QX. We to to continue strategic sheet, vision our on balance execute us
installed programs, our with far two and to in XXXX have hospitals initiate base the We three in to set near another of added with systems term. thus initiating
recent of We of capabilities Mark with will broadened ISU, pediatric. notably approval most continue CE going have of which progress forward, Senhance the applicability the for the leverage to with we FDA Senhance, have we the
Looking near-term XXXX, taken funding balance to care the of with of. needs capital
within areas, continue portfolio We effort. expansion execute development, market clinical will to our and focus evidence
now to would open like I for the line questions.
